MAPK3 and cancer: According to recent studies inhibition of ERK1/2, NF-κB pathways and increased sensitivity to all-trans retinoic acid (a ligand of retinoic acid receptors RARs) render cancer cells more sensitive to chemotherapeutic agents, due to reduced P-gp mediated efflux activity [54,76,77].